

Review Article

## Morphine-Induced Place Preference: Interactions with Neurotransmitter Systems

Mohammad Reza Zarrindast<sup>a,b,c\*</sup> and Ameneh Rezayof<sup>d</sup>

<sup>a</sup>Department of Pharmacology, School of Medicine and Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran. <sup>b</sup>Institute for Studies in Theoretical Physics and Mathematics, School of Cognitive Sciences, Tehran, Iran. <sup>c</sup>Institute for Cognitive Science Studies, Tehran, Iran. <sup>d</sup>School of Biology, University College of Sciences, University of Tehran, Tehran, Iran.

---

### Abstract

This review gives an overview of our recent findings and developments in research on brain mechanisms of morphine reward from studies using the place preference conditioning paradigm. Intracranial place conditioning methodology has become a valuable and firmly established and very widely used tool in behavioural pharmacology and drug reward mechanisms. Several studies have established that morphine induces a conditioned preference for the place in which it has been administered in rats. Transmitter systems that have been investigated with respect to their involvement in morphine reward mechanisms include dopamine, GABA, acetylcholine, adrenalin and nitric oxide, the motivational significance of which has been examined either directly, by using respective agonist or antagonist drugs. Although, considerable evidence suggested that the mesocorticolimbic DA system, which originates in the VTA and projects to the Nac, various limbic and cortical areas is a major neural substrate of the rewarding effects produced by morphine, but the role of other brain sites such as hippocampus and amygdala also exist. Overall, our intracranial place conditioning studies showed that there are a number of receptors, neuronal pathways and discrete central nervous system sites involved in the morphine reward mechanisms.

**Keywords:** Morphine; Conditioned place preference; Neurotransmitters; Reward mechanisms.

---

### Introduction

The behavioral evidence shows that opiate addiction is a complex phenomenon involving many biological and social factors (1), and was also suggested that learning and memory play an important role in the development of opiate tolerance and dependence (2, 3). Conditioned place preference (CPP), a behavioral task

often used to measure reinforcing properties of drugs, has been used to measure memory or learning of simple stimulus–reward associations (4). Several studies suggested that morphine induces a conditioned preference for the place in which it has been administered in rats (for a review see [5]). In accord with previous studies (6, 7), our data indicated that morphine induced a significant CPP, dose dependently.

It seems that the mesolimbic dopaminergic pathway projecting from the ventral tegmental area to the nucleus accumbens is a critical site

---

\* Corresponding author:  
E-mail: zarinmr@ams.as.ir

for the initiation of psychological dependence on opioids (8). Intracranial place conditioning studies have been used to show that there are a number of receptors, neuronal pathways and discrete central nervous system (CNS) sites involved in the brain reward mechanisms (for a review see [9]). Thus, it was postulated that opiates have more than one site of rewarding action, which may include the VTA (10-12), the Nac (13), the hippocampus (3, 14), the amygdala (3, 15), the medial prefrontal cortex, the lateral hypothalamus (9) and the periaqueductal gray (16).

Among the CNS regions examined, there was evidence suggesting that the mesocorticolimbic DA system, which originates in the VTA and projects to the Nac, various limbic and cortical areas is a major neural substrate of the rewarding effects produced by morphine (11, 12). It has been demonstrated that injection of morphine into the VTA produces conditioned place preference, suggesting that activating opioid receptors throughout the VTA is rewarding (9, 11, 17, 18). On the other hand, there are some report showing that unilateral infusion of the mu-opioid agonist DAMGO into the VTA produced CPP, whereas infusion of the Kappa-opioid agonist U50, 488H produced conditioned place aversion (19). Activating mu-opioid receptors within the VTA is reinforcing but that activating kappa-opioid receptors could affect different neuronal ensembles to produce place aversion (9).

Nucleus accumbans (NAc) also is a neuroanatomical substrate mediating the rewarding effects of morphine. Van Der Kooy et al. (20) reported that unilateral injections of morphine into the NAc produced CPP in rats. Contrary to these results, Olmstead and Franklin (11) reported that unilateral injection of 1.5 nmol morphine into either the shell or core of the NAc did not produce conditioned place preference. It seems that the lack of effect found by Olmstead and Franklin may be a result of using a low dose of morphine. The investigations of Bals-Kubik et al. (19) also showed that the intra-NAc administration of a kappa-opioid agonist produced conditioned place aversion (CPA). Thus, it has been suggested that activating of opioid receptors within the NAc may be positively reinforcing.

Decker and McGaugh (21) reported that morphine inhibits cholinergic activity in the hippocampus. Synaptic acetylcholine (ACh) release in the VTA has an excitatory function on DA neuronal activity (22). Although other evidences suggested that the mesolimbic dopaminergic system is necessary for the acquisition of morphine-induced CPP (23), the role of other neurotransmitter systems such as GABA (24), nitric oxide (25, 26) and glutamate (27) also exist.

Some conditioned place preference (CPP) studies suggested that the amygdala may play an important role in the reward produced by drugs of abuse (3, 28). The amygdaloid complex is composed of several different nuclei and cortical areas that are linked to each other and also to other brain regions via organized pathways (29). Among the diverse nuclei of the amygdala, it appears that the central and basolateral amygdala (CeA and BLA) are involved in arousal, expression of emotions and forming associations between environmental stimuli, the formation and expression of stimulus-reward associations and affective states, typically involving autonomic responses (30-32). The CeA is a part of the extended amygdala that connects anatomically with the nucleus accumbens (Nac) and receives dense dopaminergic afferents from the ventral tegmental area (VTA). It also has more DA terminals relative to other amygdaloid nuclei (33). Furthermore, BLA connects anatomically with Nac (34) and shares reciprocal connections with VTA (35). The basolateral amygdala (BLA), being the main part of the amygdaloid body, is a key subregion of the amygdala involved in several neurotransmitter systems such as dopamine (36), glutamate (37) and ACh (38) have been implicated in amygdala dependent mediation of stimulus-reward associations. Amygdala is important for learning tasks such as CPP that use appetitive motivation and the reinforcement is of high affective value (4). Findings in our previous experiments indicated that the amygdala has an important role in mediation of morphine-induced place preference (24, 39-41).

It was already reported that unilateral injections of the mu-opioid agonist DAMGO or morphine into the medial prefrontal cortex (MPF) did not have any effect on CPP, whereas

injections of a kappa-opioid agonist produced CPA (11, 19). Thus, it has been suggested that the MPF is involved in brain mechanisms mediating drug reward. Moreover, considerable evidence also suggested that the lateral hypothalamus may be another site supporting the reinforcing actions of morphine and mu-opioid agonists (for a review see [9]).

### **Involvement of dopaminergic system**

Some researchers claimed that the activation of different subtypes of DA receptors could be essential for the opiate reward (for a review see [5]). Furthermore, a pivotal role for dopaminergic mechanisms in opioid-induced CPP was proposed (42). Dopamine (DA) exerts its action by binding to specific membrane receptors (43). The DA receptor subtypes are divided into two major subclasses: D<sub>1</sub>-like (D<sub>1</sub> and D<sub>5</sub>) and D<sub>2</sub>-like (D<sub>2</sub>, D<sub>3</sub> and D<sub>4</sub>) (for a review see [44]). It has been suggested that the involvement of DA in opioid-induced place preference is mediated through DA receptors (40, 41). For example, the CPP produced by morphine is abolished by pretreatment with a dopamine D<sub>1</sub> receptor antagonist (45). Morphine-induced place preference is also attenuated by 6-hydroxydopamine lesion of the Nac (46). Opioids have the ability to increase DA release in the Nac (42). Moreover, injection of opioids into the VTA elicits a CPP (19) and increase DA release in the Nac (47).

Our previous experiments showed that the injection of the DA receptor agonists (D<sub>1</sub> receptor agonist: SKF38393 or D<sub>2</sub> receptor agonist: quinpirole) or antagonists (D<sub>1</sub> receptor antagonist: SCH 23390 or D<sub>2</sub> receptor antagonist: sulpiride) into the central amygdala (40, 41) or dorsal hippocampus (48) could potentiate either or inhibit morphine-induced place preference, respectively. Since pretreatment with SCH 23390 or sulpiride reversed the SKF 38393 or quinpirole response, respectively, thus, we suggest that the effect of SKF 38393 or quinpirole may be mediated through the dopamine receptors of the central amygdala or dorsal hippocampus. The distribution of D<sub>1</sub> and D<sub>2</sub> DA receptors in the nuclei of the rat amygdaloid complex estimated by quantitative light microscopy has the highest density of

[<sup>125</sup>I]iodosulpiride (DA D<sub>2</sub> receptor antagonist) binding sites in the CeA (49). Considering the anatomy and functions of the CeA, it is likely that it influences the mesocorticolimbic dopaminergic system (originating with cell bodies in the VTA that project to the Nac) that mediates opiate reward (40, 41, 50). As the CeA also projects back to the VTA and the Nac, it is likely to have an important role in the control of motivation and the effects of drug conditioned cues (33, 51). It should be noted that in our experiments (41, 48), intracranial injections of quinpirole had biphasic effects on the acquisition of CPP induced by morphine. We showed that quinpirole potentiated the acquisition of CPP induced by the lower doses of morphine (0.5 and 2.5 mg/kg), while it decreased the response induced by the higher dose (7.5 mg/kg) of morphine. Since the administration of the DA D<sub>2</sub> receptor antagonist, attenuated the potentiation or inhibition induced by quinpirole, the effect of quinpirole may be produced through a DA D<sub>2</sub> receptor mechanism. Hodge et al. (52) showed similar biphasic effects by elicited quinpirole. They reported that the microinjection of quinpirole into the Nac produced a biphasic effect on alcohol self-administration. Since the DA D<sub>2</sub>/D<sub>3</sub> receptor agonist, quinpirole, exhibits an affinity for DA D<sub>3</sub> receptors at higher doses, it appears likely that the dose-related differential action is due to the various D<sub>2</sub>-like receptor subtypes. It has further been demonstrated that the activation of DA D<sub>2</sub> and D<sub>3</sub> receptor subtypes have opposing functional consequences on behaviors (53). The activation of pre-synaptic (terminal) DA D<sub>2</sub> receptors inhibits both the DA synthesis and release. Some studies also suggest that DA D<sub>3</sub> receptors might function as both release- and synthesis-inhibiting autoreceptors in some systems (54). Therefore, we suggested that the biphasic effect of quinpirole on the acquisition of morphine-induced CPP may be either due to pre- or post-synaptic stimulation of DA D<sub>2</sub>-like receptors or may be mediated through activation of different DA receptors.

De Fonseca and colleagues (6) showed that DA has an effective role in the expression of morphine-induced place preference. The expression of morphine-induced CPP may be related to decrease in DA release in the test

session. This decrease stimulates the drug-seeking behavior evoked by environmental cues associated with morphine administration. The opposite effects of the lower and higher doses of quinpirole on the expression of the morphine-induced CPP may be related to the affinity of the drug to the DA  $D_2/D_3$  receptors that may change the DA levels. Intra-CeA administration of sulpiride by itself also decreased the expression of morphine-induced CPP. Sulpiride may block presynaptic DA  $D_2$  receptors, and so releases DA, which, in turn, activates postsynaptic DA receptors and thus reduces the expression of morphine-induced CPP. In general, our studies demonstrated for the first time that DA  $D_2$  receptors in the CeA have an important role in the acquisition and expression of morphine-induced CPP. Recent studies also support this hypothesis that the DA  $D_2$  receptor could be as important as the DA  $D_1$  receptors in morphine reward (8).

#### Involvement of GABAergic system

Some studies strongly suggested that opiates actions on a GABAergic in both the VTA and the Nac play critical roles (55). Opiates inhibit VTA GABAergic interneurons to decrease GABA release, which subsequently disinhibits VTA DA neurons, leading to an increase in Nac DA release (56). The inhibitory functions of GABA in the brain are mediated by two distinct classes of receptors, namely the GABA<sub>A/C</sub> and GABA<sub>B</sub> receptors. The GABA<sub>A/C</sub> receptors are ligand-gated  $Cl^-$  channel that mediate the fast synaptic inhibition. The GABA<sub>B</sub> receptors are linked to  $K^+$  channel via G protein and mediate slow onset and prolonged effects of GABA in the CNS (57, 58).

In a number of mammalian species, including rats, mice and monkeys have been shown that GABA<sub>B</sub> receptors modulate memory processes in learning paradigms (59). It has been also suggested that the involvement of GABA in opioid reward is mediated especially through GABA<sub>A</sub> receptors (60). Our previous study showed that the injection of the GABA<sub>A</sub> receptor agonist, muscimol into the BLA (24) significantly decreased the acquisition of morphine-induced place preference. Considering that the projection from the BLA to the Nac may act to modulate DA levels in the Nac (61), there may

be a possibility that muscimol could attenuate the morphine response through dopaminergic mechanism. Xi and Stein (56) suggested the hypothesis that GABA<sub>A</sub> receptors are located on both dopaminergic projection neurons and GABAergic interneurons in the VTA such that activating them individually will produce opposite effects on mesolimbic DA release: either direct inhibition or indirect disinhibition, respectively. It has also been suggested that the BLA may exert an inhibitory effect on the Nac, during conditions of Nac activation. Therefore, it seems that the bilateral injection of muscimol into the BLA in the presence of morphine may have an inhibitory effect on the Nac and decrease morphine reward.

In the other study, we injected the GABA<sub>B</sub> receptor agonist, baclofen into the dorsal hippocampus (62) and obtained the results as the same as muscimol response. These results are in consistence with previous observations showing that the rewarding effect of morphine, as assessed by morphine-induced place preference suppressed by microinjection of baclofen into the VTA (10). In addition, some studies reported that GABA<sub>B</sub> receptor agonists decrease cocaine reward (63, 64). It has been also shown that lesions of the dorsal hippocampus, but not the ventral hippocampus, attenuate cocaine-CCP (65). Furthermore, it has been suggested that GABA<sub>B</sub> receptor agonists attenuate the reinforcing effects of cocaine, nicotine, heroin and ethanol through a modulation of dopamine transmission (66). Baclofen has been shown to decrease the activity of dopamine neurons and decrease extracellular dopamine levels in the VTA and nucleus accumbens (67). The activation of the mesolimbic dopamine (DA) system by morphine is essential for morphine reward, and also intra-CA1 injection of baclofen induced inhibition of morphine CPP, thus it seems that the inhibitory effect of baclofen to be also produced via an interaction with dopamine system.

On the other hand, our investigations indicated that microinjection of the GABA<sub>A</sub> receptors antagonist, bicuculline into the BLA, during acquisition of place preference, increased the morphine CPP. It has been suggested that blockade of postsynaptic GABA<sub>A</sub> receptors by bicuculline, which increases brain GABA



levels, may accelerate the development of morphine dependence (68). Furthermore, GABA antagonists can activate VTA DA neurons and increase DA release in the Nac (69). Yan (70) also reported that local application of bicuculline increases dopamine release in the Nac via a receptor mediated process. Considering the previous results and that the BLA projects to the Nac, there may be a possibility that in our data (24), bicuculline in the BLA potentiates the dopamine properties of morphine in the Nac through such a pathway. Our results also showed that pretreatment with bicuculline during conditioning, attenuated the decrease of morphine reward by muscimol. Therefore, the muscimol response may be mediated through GABA<sub>A</sub> receptors. These results are consistent with previous observations that showed microinjection of muscimol into VTA produced a dose-dependent increase in motor activity. This effect was antagonized by intra-tegmental injection of bicuculline or peripheral administration of haloperidol (71), suggesting that the effects of bicuculline on accumbal dopamine levels were mediated through GABA<sub>A</sub> receptors (72). It is also interesting to note that the bilateral microinjection of GABA<sub>B</sub> receptors antagonist, phaclofen into the dorsal hippocampus can significantly increase morphine-induced place preference (62). It has also reported that pretreatment with phaclofen during conditioning, attenuated the decrease of morphine reward by baclofen. Therefore, GABA<sub>B</sub> receptor mechanism is involved in the inhibition of morphine-induced CPP.

Furthermore, in a set of experiments, we also tested the effects of the intra-BLA administration of muscimol or bicuculline on the expression of morphine-induced place preference (24). The results showed that administration of bicuculline, but not muscimol, before testing prevented the expression of morphine-induced place preference. Since bicuculline potentiated acquisition of morphine-induced CPP and attenuated the expression of the opioid effect, therefore, GABA<sub>A</sub> receptors in the BLA may be differentially involved in the acquisition and expression of morphine CPP. We also examined the effects of intra-dorsal hippocampus administration of the GABA<sub>B</sub> receptor agonist

or antagonist on the expression of morphine CPP. The results showed that administration of baclofen, but not phaclofen, before testing prevented the expression of morphine-induced place preference. Since baclofen attenuated acquisition and expression of morphine-induced CPP, therefore, GABA<sub>B</sub> receptors in the CA1 regions of dorsal hippocampus may interact with dopaminergic system and thus can reduce the expression of morphine reward. Thus, our findings support the role of GABA<sub>A</sub> and GABA<sub>B</sub> receptors in the actions of morphine and further suggest that dorsal hippocampus and amygdala GABAergic system may be relevant to the rewarding effects of drugs of abuse and are involved in mediating morphine CPP.

### **Involvement of cholinergic system**

It is well known that there exists an interaction between opioid and the cholinergic systems (73-75). Moreover, it is also reported that  $\mu$  and  $\delta$  receptors located on cholinergic terminals, are normally under tonic inhibition by the opiate system (76). Decker and McGaugh (21) reported that morphine inhibits cholinergic activity in the hippocampus. Synaptic acetylcholine (ACh) release in the VTA has an excitatory function on DA neuronal activity (22, 77).

Our previous studies showed that bilateral injections of the cholinesterase inhibitor, physostigmine or the nicotinic acetylcholine receptor agonist, nicotine into the dorsal hippocampus (78) or amygdala (40) during acquisition of place preference, potentiated the morphine-induced place preference. It has been reported that combined administration of morphine and physostigmine results in a strong, highly significant antinociceptive effect (79). Basile and coworkers (80) demonstrated that the rewarding effects of morphine, as measured in the CPP paradigm, are reduced in M<sub>5</sub> muscarinic receptor-deficient mice. It may be possible that physostigmine in combination with morphine induces its rewarding effect through muscarinic receptor mechanisms. On the other hand, it has been suggested that central nicotinic receptor stimulation, especially those located in the VTA, increases dopamine release in the nucleus accumbens (81-84). Both nicotine and morphine may produce a reinforcing effect due

to facilitating dopaminergic transmission (85). Considering the fact that there is an interaction between nicotinic receptors and opioid systems in controlling the release of dopamine and the induction of reward, it seems likely that intra-dorsal hippocampus, -amygdala or -VTA administration of nicotine potentiates dopamine properties of morphine.

In several investigations, we reported that the blockade of muscarinic or nicotinic receptors of dorsal hippocampus (78) or amugdala (40) by atropine or mecamlamine inhibited the morphine-induced place preference. Furthermore, our data in previous studies revealed that administration of atropine or mecamlamine reversed the physostigmine or nicotine response respectively; and therefore the effect of physostigmine may be mediated through muscarinic receptors. In agreement with our data, other investigators have shown that injections of atropine into the VTA inhibited brain stimulation reward (86). It has also indicated that administration of mecamlamine disrupts cocaine-induced place preference (87) as well as decreasing alcohol's effects on the mesolimbic dopamine system (88, 89). It has been suggested that the central nicotinic receptors appear to facilitate the rewarding and reinforcing effects and mecamlamine blocks the nicotine-induced behavioral responses (90-95). Nicotine-induced accumbal dopamine release was inhibited by mecamlamine (84). Our data may be similar to results obtained by Garcia-Rebollo and coworkers (96) who showed that the administration of nicotine in the CA1 region of dorsal hippocampus has a detrimental dose-dependent effect on acquisition of the lever-press response in alcohol drinkers and antagonized by mecamlamine co-administration.

#### **Involvement of nitric oxide**

Nitric oxide (NO) is formed enzymatically from L-arginine, a nitric oxide (NO) precursor by NO synthase (NOS) following the activation of NMDA receptor (97). NO has been documented to participate in numerous physiological and pathophysiological processes (98). The synaptic transmission in the central and peripheral nervous system seems to be modulated by NO (99). NO is a neurotransmitter in the central

nervous system, and an important messenger molecule in a number of organ systems (100). NO has some known implications in opiates dependence, as NOS inhibitors attenuate signs of opiates withdrawal (100) and prevent morphine tolerance (101). NO is involved in the rewarding properties of opiates (102). Both activation and inhibition of nitric oxide synthesis may alter morphine induced place preference (103, 104). Thus, NO is assumed to play a role in the place preference induced by morphine. There is an interaction between the NO system and the dopaminergic neuronal system (105). In addition, previous studies suggested that endogenous nitric oxide (NO) could play a role in the modulation of dopaminergic effects elicited by morphine (104, 106).

Nucleus accumbens is one of the regions in which the diffusible gas NO has been implicated in the control of dopamine release (107). It is determined that dopamine D<sub>3</sub> receptor density is modified following NO generation and the density of high affinity dopamine D<sub>2</sub> receptors decreases in the nucleus accumbens and NO is very much involved in the expression of the associative increase in extracellular dopamine in the nucleus accumbens (108). In the shell of the nucleus accumbens, NOS is localized to the cytoplasm of spiny somata and dendrites some of which contain *N*-Methyl-D-aspartate (NMDA) receptors (107). Furthermore, pharmacological studies also suggested that glutamate releases NO through activation of NMDA receptor thus implying that NMDA receptors are present on cells producing NO (109). It is also revealed that glutamate receptor antagonists can block the acquisition and/or expression of morphine reward and antagonism of NMDA receptor functions within the nucleus accumbens is shown to reduce the expression of the psychostimulant and reinforcing properties of cocaine (110).

Our previous studies also showed that the injection of L-arginine into the ventral tegmental area (111), nucleus accumbens (26), dorsal hippocampus (103) or central amygdale (25) significantly potentiated morphine-induced place preference. It has been reported that L-arginine induced dopamine release from the striatum in vivo that can be markedly reduced by NOS inhibitors (112). Also endogenously produced

NO is involved in stimulating dopamine release following activation of NMDA receptors located on dopaminergic nerve terminals in the nucleus accumbens. Since NO is a membrane-permanent gas, which can diffuse out to act on neighboring neurons, it is likely that NO synthesized in neurons postsynaptic to mesolimbic dopamine fibers may influence presynaptic processes to stimulate dopamine release in the nucleus accumbens (113). Furthermore, it has recently been reported that the associative type of sensitization to d-amphetamine is expressed as an NO-dependent dramatic increases in extracellular dopamine in the nucleus accumbens (114). Therefore, our data may be in agreement with a previous report that NO stimulated dopamine release in the nucleus accumbens (115).

On the other hand our investigations indicated that intra-VTA, -NAc or -CeA administration of *N*<sup>G</sup>-nitro-L-arginine methyl ester (L-NAME) decreased the conditioned place preference induced by morphine and also the response of different doses of L-arginine was decreased by L-NAME. The results are in agreement with previous data that showed the blockade of NO synthesis with L-NAME reduced the reinforcing properties of cocaine (110). Intraperitoneal administration of NOS inhibitor, L-NOARG (L-N-nitroarginine), before and during the chronic administration of morphine has been also shown to block the acquisition of morphine place preference (104), while administration of a NOS inhibitor never showed any significant effect of place preference (104). Another neuronal NOS inhibitor, 7-nitronidazole has also been shown to block conditioned place preference induced by cocaine (102), nicotine (116) and alcohol (117). The possibility may exist that L-NAME decreases the dopamine release in the nucleus accumbens by morphine, thus attenuation of morphine-induced place preference can be observed. This can be also supported by our data which shows pretreatment with L-NAME reversed the increase in morphine place preference by administration of L-arginine in the conditioning sessions (26). Therefore, it can be concluded that acquisition of morphine place preference might be mediated via activation of the NO system in the nucleus accumbens in the present experiments. our results also showed that NO may be involved

in the acquisition and expression of morphine-induced place preference.

### Involvement of adrenergic

Several studies have shown that the alpha-adrenergic and opioid systems can interact in a complex manner. Morphine tends to inhibit noradrenaline release from human neuroblastoma cells (118). There are also reports showing that opioids increase the turnover of norepinephrine (119).

The noradrenergic and opioid systems have been shown to be involved in the development and expression of opioid dependence (for a review, see [120]). The rats tolerant to the antinociceptive effects of morphine showed cross-tolerance to the effect of norepinephrine (121) and  $\alpha_2$ -adrenoceptor agonist, clonidine (122). Furthermore, rats tolerant to the antinociceptive effect of clonidine showed cross-tolerance to the effects of morphine (123). Clonidine also attenuated some of the signs of morphine withdrawal in rats (124) as well as the signs of morphine withdrawal in humans (125). Acute administration of the adrenoceptor antagonist, yohimbine, increased the physical effects of morphine withdrawal in rats (126), suggesting that  $\alpha_2$ -adrenoceptors are involved in the development of physical dependence upon opioids (127). It has also been shown that signs of discriminative-stimulus (128) and development of conditioned opiate withdrawal effects of morphine (129) may be enhanced by clonidine.

Although there is a report that indicates no important role for noradrenergic pathways in CPP (130), evidence from many different studies revealed that adrenergic drugs are involved in CPP over a range of doses. For example, it has indicated that  $\alpha$ -2 adrenergic agonists and antagonists can induce CPP or CPA (see review [5]). Morphine-induced CPP may be related to dopaminergic mechanism(s) (41) and several studies in mice and rats revealed the existence of interactions between adrenergic and dopaminergic systems (131). Several other studies (131- 133) showed that phenylephrine or clonidine inhibits and also prazosin or yohimbine increases the expression of morphine-induced CPP. These results indicated that both agonists

of  $\alpha_1$ - and  $\alpha_2$ -adrenoceptors have similar effects and thus, there is the possibility that activation of these receptors inhibit the expression of morphine CPP. In contrast, the data showed that the adrenoceptor antagonists enhanced the morphine response. The conditioned opiate withdrawal represents the negative reinforcement properties of opiates (129), while the CPP paradigm is developed to investigate the positive reinforcement properties of natural rewards and abused drugs (5, 130, 134). Because the adrenoceptor agonists and antagonists alter the morphine effect in our previous study (133), one may conclude that brain adrenergic systems have an important role in the expression of conditioned reward induced by morphine. Several studies showed that clonidine decreased, while yohimbine increased the acquisition of morphine conditioning (5, 132, 135). Overall, in agreement with others (131, 132), the obtained results indicated involvement of alpha adrenoceptors in the expression and acquisition of morphine CPP.  $\alpha_2$ -adrenoceptor agonist, clonidine, acts primarily at presynaptic noradrenergic autoreceptors to decrease noradrenaline activity. It alleviated the behavioral symptoms of opiate withdrawal in rats and humans. Clonidine also blocked the rewarding effect of morphine in opiate-withdrawn rats as well as the aversive properties of the withdrawal itself (136). It has been shown that the drug could produce CPP (5) or CPA (135). Yohimbine, the  $\alpha_2$ -adrenoceptor antagonist, which is clinically available and used to treat erectile impotence (137), was found to produce CPA. Moreover, the  $\alpha_1$ -adrenoceptor antagonist prazosin, which has been shown to have a preference for  $\alpha_2$ -adrenoceptor subtypes (138), did not produce any effect in this respect (5).

### Conclusion

Conditioned place preference (CPP), a task often used to measure reinforcing properties of drugs, such as morphine. There are a number of receptors, neuronal pathways and discrete central nervous system sites involved in the morphine reward mechanisms. However, it seems that the mesolimbic dopaminergic pathway projecting from the ventral tegmental area to the nucleus

accumbens is a critical site for the initiation of psychological dependence on opioids, but our studies demonstrated that other neurotransmitter systems may be involved in the morphine reward.

### References

- (1) Wang NJ, Wu CF and Pei G. Spatial learning and morphine-rewarded place preference negatively correlates in mice. *Pharmacol. Biochem. Behav.* (2001) 68: 389-394
- (2) Fan GH, Wang LZ, Qui HC, Ma L and Pei G. Inhibition of calcium/calmodulin dependent protein kinase II in rat hippocampus attenuates morphine tolerance and dependence. *Mol. Pharmacol.* (1999) 56: 39-45
- (3) Lu L, Zeng Sh, Liu D and Ceng X. Inhibition of the amygdala and hippocampal calcium/calmodulin-dependent protein kinase II attenuates the dependence and relapse to morphine differently in rats. *Neurosci. Lett.* (2000) 291: 191-195
- (4) McIntyre CK, Ragozzino ME and Gold PE. Intra-amygdala infusions of scopolamine impair performance on a conditioned place preference task but not a spatial radial maze task. *Behav. Brain Res.* (1998) 95: 219-226
- (5) Tzschentke TM. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. *Prog. Neurobiol.* (1998) 56: 613-672
- (6) De Fonseca FRD, Rubio P, Martin-Caldon JL, Caine SB, Koob GF and Navarro M. The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preference. *Eur. J. Pharmacol.* (1995) 274: 47-55
- (7) Shippenberg TS, Heidbreder CH and Lefevour A. Sensitization to the conditioned rewarding effects of morphine: pharmacology and temporal characteristics. *Eur. J. Pharmacol.* (1996) 299: 33-39
- (8) Manzanedo C and Aguilar MA, Rodriguez-Arias M, Minarro J. Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice. *Behav. Brain Res.* (2001) 121: 189-197
- (9) McBride WJ, Murphy JM and Ikemoto S. Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies. *Behav. Brain Res.* (1999) 101: 129-152
- (10) Tsuji M, Nakagawa Y, Ishibashi Y, Yoshii T, Takashima T and Shimada M. Activation of ventral tegmental GABAB receptors inhibits morphine-induced place preference in rats. *Eur. J. Pharmacol.* (1996) 313: 169-173
- (11) Olmstead MC and Franklin BJ. The development of a conditioned place preference to morphine: Effects of microinjections into various CNS sites. *Behav. Neurosci.* (1997) 111: 1324-1334
- (12) Olmstead MC and Franklin B. The development of a



- conditioned place preference to morphine: Effects of lesions of various CNS sites. *Behav. Neurosci.* (1997) 111: 1313-1323
- (13) Laviolette SR, Nader K and van der Kooy D. Motivational state determines the functional role of the mesolimbic dopamine system in the mediation of opiate reward processes. *Behav. Brain Res.* (2002) 129: 17-29
- (14) Corrigan WA and Linseman MA. Conditioned place preference produced by intra-hippocampal morphine. *Pharmacol. Biochem. Behav.* (1988) 30: 787-789
- (15) Kelsy JE and Arnold SR. Lesions the dorsomedial amygdala, but not the nucleus accumbens, reduce the aversiveness of morphine withdrawal in rats. *Behav. Neurosci.* (1994) 108: 1119-1127
- (16) Motta V and Brandao ML. Aversive and antiaversive effects of morphine in the dorsal periaqueductal gray of rats submitted to the elevated plus-maze test. *Pharmacol. Biochem. Behav.* (1993) 44: 119-125
- (17) Phillips AG and Le Piane FG. Reinforcing effects of morphine microinjection into the ventral tegmental area. *Pharmacol. Biochem. Behav.* (1982) 5: 225-229
- (18) Steffensen SC, Stobbs SH, Colago EE, Lee RS, Koob GF, Gallegos RA, Henriksen SJ. Contingent and non-contingent effects of heroin on mu-opioid receptor-containing ventral tegmental area GABA neurons. *Exp. Neurol.* (2006) 202: 139-51
- (19) Bals-Kubik R, Ableitner A, Herz A and Shippenberg TS. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. *J. Pharmacol. Exp. Ther.* (1993) 264: 489-495
- (20) Van der Kooy D, Mucha RF, O'shaughnessy M and Buceniek P. Reinforcing effects of brain microinjection of morphine revealed by conditioned place preference. *Brain Res.* (1982) 243: 107-117
- (21) Decker MW and McGaugh JL. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. *Synapse* (1991) 7: 151-168
- (22) Greba Q, Munro LJ and Kokkinidis L. The involvement of ventral tegmental area cholinergic muscarinic receptors in classically conditioned fear expression as measured with fear-potentiated startle. *Brain Res.* (2000) 870: 135-141
- (23) Wise RA. Drug-activation of brain reward pathways. *Drug Alcohol Depend.* (1998) 51: 13-22
- (24) Zarrindast MR, Ahmadi S, Haeri-Rohani A, Rezayof A, Jafari MR and Jafari-Sabet M. GABA(A) receptors in the basolateral amygdala are involved in mediating morphine reward. *Brain Res.* (2004) 1006: 49-58
- (25) Zarrindast MR, Karami M, Sepehri H and Sahraei H. Influence of nitric oxide on morphine-induced conditioned place preference in the rat central amygdala. *Eur. J. Pharmacol.* (2002) 453: 81-89
- (26) Gholami A, Haeri-Rohani A, Sahraei H and Zarrindast MR. Nitric oxide mediation of morphine-induced place preference in the nucleus accumbens of rat. *Eur. J. Pharmacol.* (2002) 449: 269-277
- (27) Tzschentke TM and Schmidt WJ. N-Methyl-D aspartic acid-receptor antagonists block morphine-induced conditioned place preference in rats. *Neurosci. Lett.* (1995) 193: 37-40
- (28) O'Dell LE, Sussman AN, Meyer KL and Neisewander JL. Behavioral effects of psychomotor stimulant infusions into amygdaloid nuclei. *Neuropsychopharmacology* (1999) 20: 591-602
- (29) Pitkanen A, Savander V and LeDoux JE. Organization of intra-amygdaloid circuitries in the rat: an emerging framework for understanding functions of the amygdala. *Trends Neurosci.* (1997) 20: 517-523
- (30) Kaada BR. Stimulation and regional ablation of the amygdaloid complex with reference to functional representations. In: Eleftheriou BE. (Ed.) *The Neurobiology of the Amygdala*. New York, Plenum (1972) 205-282
- (31) Kapp BS, Whalen PJ, Supple WF and Pascoe JP. Amygdaloid contributions to conditioned arousal and sensory information processing. In: Aggleton JP. (Ed.) *The Amygdala: Neurobiological Aspects of Emotion, Memory, and Mental Dysfunction*. Wiley-Liss, New York (1992) 229-54
- (32) Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P and Robbins TW. Associative processes in addiction and reward: the role of amygdala- ventral striatal subsystems. *Ann. N. Y. Acad. Sci.* (1999) 877: 412-438
- (33) Woodward J, Chang JY, Janak P, Azarov A and Anstrom K. Mesolimbic neuronal activity across behavioral states. *Ann. N.Y. Acad. Sci.* (1999) 877: 91-112
- (34) Johnson LR, Aylward RL, Hussain Z and Totterdell S. Input from the amygdala to the rat nucleus accumbens: its relationship with tyrosine hydroxylase immunoreactivity and identified neurons. *Neuroscience* (1994) 61: 851-865
- (35) Asan E. The catecholaminergic innervation of the rat amygdala. *Adv. Anat. Embryol. Cell Biol.* (1998) 142: 1-118
- (36) See RE, Kruzich PJ and Grimm JW. Dopamine, but not glutamate, receptor blockade in the basolateral amygdala attenuates conditioned reward in a rat model of relapse to cocaine-seeking behavior. *Psychopharmacology* (2001) 154: 301-310
- (37) Burns LH, Everitt BJ and Robbins TW. Intra-amygdala infusion of the N-methyl- D-aspartate receptor antagonist AP5 impairs acquisition but not performance of discriminated approach to an appetitive CS. *Behav. Neural. Biol.* (1994) 61: 242-250
- (38) See RE, McLaughlin J and Fuchs A. Muscarinic receptor antagonism in the basolateral amygdala blocks acquisition of cocaine-stimulus association in a model of relapse to cocaine-seeking behavior in rats. *Neuroscience* (2003) 117: 477-483
- (39) Zarrindast MR., Rezayof A, Sahraei H, Haeri-Rohani A and Rassouli Y. Involvement of dopamine D1 receptors of the central amygdala on the acquisition

- and expression of morphine-induced place preference in rat. *Brain Res.* (2003b) 965: 212-221
- (40) Zarrindast MR, Fattahi Z, Rostami P and Rezaeif A. Role of the cholinergic system in the rat basolateral amygdala on morphine-induced conditioned place preference. *Pharmacol. Biochem. Behav.* (2005) 82: 1-10
  - (41) Rezaeif A, Zarrindast MR, Sahraei H and Haeri-Rohani A. Involvement of dopamine D<sub>2</sub> receptors of the central amygdala on the acquisition and expression of morphine-induced place preference in rat. *Pharmacol. Biochem. Behav.* (2002) 74: 187-197
  - (42) Van Ree JM, Gerrits MAFM and Vanderschuren LJMJ. Opioids, Reward and addiction: An Encounter of Biology, Psychology, and Medicine. *Pharmacol. Rev.* (1999) 51: 341-396
  - (43) Gingrich JA and Caron MG. Recent advances in the molecular biology of dopamine receptors. *Annu. Rev. Neurosci.* (1993) 16: 299-321
  - (44) Vallone D, Roberto P and Emiliana B. Structure and function of dopamine receptors. *Neurosci. Biobehav. Rev.* (2000) 24: 125-132
  - (45) Suzuki T, Funada M, Narita M, Misawa M and Nagase H. Morphine-induced place preference in the CXBK mouse: characterization of  $\mu$  opioid receptor subtypes. *Brain Res.* (1993) 602: 45-52
  - (46) Shippenberg TS, Bals-kubik R, Huber A and Herz A. Neuroanatomical substrates mediating the aversive effects of D-1 dopamine receptor antagonists. *Psychopharmacol.* 103 (1991) 209-214
  - (47) Leone P, Pocock D and Wise RA. Morphine-dopamine interaction: ventral tegmental morphine increases nucleus accumbens dopamine release. *Pharmacol. Biochem. Behav.* (1991) 39: 469-472
  - (48) Rezaeif A, Zarrindast MR, Sahraei H and Haeri-Rohani A. Involvement of dopamine receptors of the dorsal hippocampus on the acquisition and expression of morphine-induced place preference in rats. *J. Psychopharmacol.* (2003) 17: 415-423
  - (49) Scibilia RJ, Lachowicz JE and Kilts CD. Topographic nonoverlapping distribution of D1 and D2 dopamine receptors in the amygdaloid nuclear complex of the rat brain. *Synapse* (1992) 11: 146-154
  - (50) Rezaeif A, Golhasani-Keshtan F, Haeri-Rohani A, Zarrindast MR. Morphine-induced place preference: involvement of the central amygdala NMDA receptors. *Brain Res.* (2007) 1133: 34-41
  - (51) Wallace DM, Magnuson DJ and Gray TS. Organization of amygdaloid projections to dopaminergic, noradrenergic, adrenergic cell groups in the rat. *Brain Res. Bull.* (1992) 28: 447-454
  - (52) Hodge CW, Samson HH and Chappelle AM. Alcohol self-administration: further examination of the role of dopamine receptors in the nucleus accumbens. *Alcoholism* (1997) 21: 1083-1091
  - (53) Richtand NM, Woods SC, Berger P and Strakowski SM. D<sub>3</sub> dopamine receptor, behavioral sensitization, and psychosis. *Neurosci. Biobehav. Rev.* (2001) 25: 427-443
  - (54) Tang L, Todd RD and O'Malley KL. Dopamine, D2 and D3 receptors inhibit dopamine release. *J. Pharmacol. Exp. Ther.* (1994) 270: 475-459
  - (55) Xi ZX and Stein EA. GABAergic mechanisms of opiate reinforcement. *Alcohol.* (2002) 37: 485-494
  - (56) Xi ZX and Stein EA. Nucleus accumbens dopamine release modulation by mesolimbic GABA<sub>A</sub> receptors-an *in vivo* electrochemical study. *Brain Res.* (1998) 798: 156-165
  - (57) Couve A, Moss SJ and Pangalos MN. GABA<sub>B</sub> receptors: a new paradigm in G protein signaling. *Mol. Cell Neurosci.* (2000) 16: 296-312
  - (58) Li T, Qadri F and Moser A. Neuronal electrical high frequency stimulation modulates presynaptic GABAergic physiology. *Neurosci. Lett.* (2004) 371: 117-121
  - (59) Castellano C, Brioni JD, Nagahara AH and McGaugh JL. Post-training systemic and intra-amygdala administration of the GABA<sub>B</sub> agonist baclofen impairs retention. *Behav. Neural. Biol.* (1989) 52: 170-179
  - (60) Laviolette SR and van der Kooy D. GABA<sub>A</sub> receptors in the ventral tegmental area control bidirectional reward signaling between dopaminergic and non-dopaminergic neural motivational systems. *Eur. J. Neurosci.* (2001) 13: 1009-1015
  - (61) Jackson ME and Moghaddam B. Amygdala regulation of nucleus accumbens dopamine output is governed by the prefrontal cortex. *J. Neurosci.* (2001) 21: 676-681
  - (62) Zarrindast MR, Massoudi R, Sepehri H and Rezaeif A. Involvement of GABA<sub>B</sub> receptors of the dorsal hippocampus on the acquisition and expression of morphine-induced place preference in rats. *Physiol. Behav.* (2006) 87: 31-38
  - (63) Brebner K, Froestl W, Andrews M, Phelan R and Roberts DC. The GABA<sub>B</sub> agonist CGP 44532 decreases cocaine self-administration in rats: demonstration using a progressive ratio and a discrete trials procedure. *Neuropharmacology* (1999) 38: 1797-1804
  - (64) Campbell UC, Lac ST and Carroll ME. Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats. *Psychopharmacology* (1999) 143: 209-214
  - (65) Meyers RA, Zavala AR and Neisewander JL. Dorsal, but not ventral, hippocampal lesions disrupt cocaine place conditioning. *Neuroreport* (2003) 14: 2127-2131
  - (66) Cousins MS, Roberts DC and de Wit H. GABA<sub>B</sub> receptor agonists for the treatment of drug addiction: a review of recent findings. *Drug Alcohol Depend.* (2002) 65: 209-220
  - (67) Yoshida M, Yokoo H, Tanaka T, Emoto H and Tanaka M. Opposite changes in the mesolimbic dopamine metabolism in the nerve terminal and cell body sites induced by locally infused baclofen in the rat. *Brain Res.* (1994) 636: 111-114
  - (68) Ho IK, Loh HH and Way EL. Pharmacological

- manipulation of gamma-aminobutyric acid (GABA) in morphine analgesia, tolerance and physical dependence. *Life Sci.* (1976) 18: 1111-1123
- (69) Ikemoto S, Kohl RR and McBride WJ. GABA<sub>A</sub> receptor blockade in the anterior ventral tegmental area increases extracellular levels of dopamine in the nucleus accumbens of rats. *J. Neurochem.* (1997) 69: 137-143
- (70) Yan Q. Focal bicuculline increases extracellular dopamine concentration in the nucleus accumbens of freely moving rats as measured by in vivo microdialysis. *Eur. J. Pharmacol.* (1999) 385: 7-13
- (71) Kalivas PW, Duffy P and Eberhardt H. Modulation of A10 dopamine neurons by g-aminobutyric acid agonists. *J. Pharmacol. Exp. Ther.* (1990) 253: 858- 866
- (72) Yan Z and Surmeier DJ. D5 dopamine receptors enhance Zn<sup>2+</sup>-sensitive GABA(A) currents in striatal cholinergic interneurons through a PKA/PP1 cascade. *Neuron* (1997) 19: 1115-1126
- (73) Walker DL, McGlynn T and Grey C. Ragozzino M and Gold PE. Naloxone modulates the behavioral effects of cholinergic agonists and antagonists. *Psychopharmacology* (1991) 105: 57-62
- (74) Sharif SI and el-Kadi AO. The role of cholinergic systems in the expression of morphine withdrawal. *Neurosci. Res.* (1996) 25: 155-160
- (75) Li Z, Wu CF, Pei G and Xu NJ. Reversal of morphine-induced memory impairment in mice by withdrawal in Morris water maze: possible involvement of cholinergic system. *Pharmacol. Biochem. Behav.* (2001) 68: 507-513
- (76) Heijna MH, Padt M, Hogenboom F, Portoghese PS, Mulder AH and Schoffelemeier AN. Opioid receptor-mediated inhibition of dopamine and acetylcholine release from slices of rat nucleus accumbens, olfactory tubercle and frontal cortex. *Eur. J. Pharmacol.* (1990) 181: 267- 278
- (77) Calabresi P, Lacey MG and North RA. Nicotinic excitation of rat ventral tegmental neurones *in vitro* studied by intracellular recording. *Br. J. Pharmacol.* (1989) 98: 135-140
- (78) Rezayof A, Razavi S, Haeri-Rohani H, Rassouli Y and Zarrindast MR. GABA(A) receptors of hippocampal CA1 regions are involved in the acquisition and expression of morphine-induced place preference. *Eur. Neuropsychopharmacol.* (2006) In press
- (79) Beilin B, Nemirovsky AY, Zeidel A, Maibord E, Zelman V and Katz RL. Systemic physostigmine increases the antinociceptive effect of spinal morphine. *Pain* (1997) 70: 217-221
- (80) Basile AS, Fedorova I, Zapata A, Liu X, Shippenberg T, Duttaroy A, Yamada M and Wess J. Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia. *Proc. Natl. Acad. Sci. U. S. A.* (2002) 99: 11452-11457
- (81) Clarke PB, Fu DS, Jakubovic A and Fibiger HC. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. *J. Pharmacol. Exp. Ther.* (1988) 246: 701-708
- (82) Connelly MS and Littleton JM. Lack of stereoselectivity in ability of nicotine to release dopamine from rat synaptosomal preparations. *J. Neurochem.* (1983) 41: 1297-1302
- (83) Imperato A, Mulas A and Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. *Eur. J. Pharmacol.* (1986) 132: 337-338
- (84) Nisell M, Nomikos GG and Svensson TH. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. *Synapse* (1994) 16: 36-44
- (85) Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. *Eur. J. Pharmacol.* (2000) 393: 295-314
- (86) Yeomans J and Baptista M. Both nicotinic and muscarinic receptors in ventral tegmental area contribute to brain-stimulation reward. *Pharmacol. Biochem. Behav.* (1997) 57: 915-921
- (87) Zachariou V, Caldarone BJ, Weathers-Lowin A, George TP, Elsworth JD, Roth RH, Changeux JP and Picciotto MR. Nicotine receptor inactivation decreases sensitivity to cocaine. *Neuropsychopharmacology* (2001) 24: 576-589
- (88) Blomqvist O, Engel JA, Nissbrandt H and Soderpalm B. The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine. *Eur. J. Pharmacol.* (1993) 249: 207-213
- (89) Ericson M, Blomqvist O, Engel JA and Soderpalm B. Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine. *Eur. J. Pharmacol.* (1998) 358: 189-196
- (90) Ericson M, Olausson P, Engel JA and Soderpalm B. Nicotine induces disinhibitory behavior in the rat after subchronic peripheral nicotinic acetylcholine receptor blockade. *Eur. J. Pharmacol.* (2000) 397: 103-111
- (91) Bevins RA and Palmatier MI. Extending the role of associative learning processes in nicotine addiction. *Behav. Cogn. Neurosci. Rev.* (2004) 3: 143-158
- (92) Nakahara D. Influence of nicotine on brain reward systems: study of intracranial self-stimulation. *Ann. N. Y. Acad. Sci.* (2004) 1025: 489-490
- (93) Olausson P, Jentsch JD and Taylor JR. Nicotine enhances responding with conditioned reinforcement. *Psychopharmacology* (2004) 171: 173-178
- (94) Panagis G, Nisell M, Nomikos GG, Chergui K and Svensson TH. Nicotine injections into the ventral tegmental area increase locomotion and Fos-like immunoreactivity in the nucleus accumbens of the rat. *Brain Res.* (1996) 730: 133-142
- (95) Stoleran IP, Garcha HS and Mirza NR. Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats. *Psychopharmacology* (1995) 117: 430-437
- (96) Garcia-Rebollo Y, Darbra S and Ferre N.

- Intrahippocampal nicotine in alcohol drinking rats--effects on lever-press response. *Eur. Neuropsychopharmacol.* (2005) 15: 43-49
- (97) Moncada S, Palmer RMJ and Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. *Pharmacol. Rev.* (1991) 43: 109-142
- (98) Moncada S and Higgs A. The L-arginine-nitric oxide pathway. *New Engl. J. Med.* (1993) 329: 2002-2012
- (99) Meller ST and Gebhart GF. Nitric oxide and nociceptive processing in the spinal cord. *Pain* (1993) 52: 127-136
- (100) Yamada K and Nabeshima T. Nitric oxide and cyclic GMP signaling pathway in learning and memory processes. *Curr. Top. Pharmacol.* (1998) 4: 77-86
- (101) Kimes SA, Vaupel DM and London ED. Attenuation of some signs of opioid withdrawal by inhibitors of nitric oxide synthase. *Psychopharmacology* (1993) 112: 521-524
- (102) Itzhak Y, Martin JL, Black MD and Huang PL. The role of neuronal nitric oxide synthase in cocaine-induced conditioned place preference. *Neuroreport.* (1998) 9: 2485-2488
- (103) Karami M, Zarrindast MR, Sepehri H and Sahraei H. Role of nitric oxide in the rat hippocampal CA1 area on morphine-induced place preference. *Eur. J. Pharmacol.* (2002) 449: 113-119
- (104) Kivastik T, Rutkauskaitė J and Zharkovsky A. Nitric oxide synthesis inhibition attenuates morphine-induced place preference. *Pharmacol. Biochem. Behav.* (1996) 53: 1013-1015
- (105) Kiss JP, Hennings EC, Zsilla G and Vizi ES. A possible role of nitric oxide in the regulation of dopamine transporter function in the striatum. *Neurochem. Int.* (1999) 34: 345-350
- (106) Calignano A, Persico P, Mancuso F and Sorrentino L. Endogenous nitric oxide modulates morphine-induced changes in locomotion and food intake in mice. *Eur. J. Pharmacol.* (1993) 231: 415-419
- (107) Gracy KN and Pickel VM. Ultrastructural localization and comparative distribution of nitric oxide synthase and N-methyl-D-aspartate receptors in the shell of the rat nucleus accumbens. *Brain Res.* (1997) 747: 259-272
- (108) Wallace DR and Booze RM. Upregulation of (+)-7-hydroxy-N,N-di-n-[<sup>3</sup>H]-2-aminotetralin binding following intracerebroventricular administration of nitric oxide generator. *Neurochem. Res.* (1997) 22: 163-170
- (109) Abecava T. Experimental study of methamphetamine psychosis role of glutamate and nitric oxide in methamphetamine-induced dopaminergic and serotonergic neurotoxicity in the rat brain. *Hokkaido Igaku Zasshi* (1997) 72: 113-126
- (110) Pulvirenti L, Balducci C and Koob GF. Inhibition of nitric oxide synthesis reduces intravenous cocaine self-administration in the rat. *Neuropharmacology* (1996) 35: 1811-1814
- (111) Gholami A, Zarrindast MR, Sahraei H and Haeri-Rohani A. Nitric oxide within the ventral tegmental area is involved in mediating morphine reward. *Eur. J. Pharmacol.* (2003) 458: 119-128
- (112) Strasser A, McCarron RM, Ishii H, Stanimirovic D and Spatz M. L-arginine induces dopamine release from the striatum *in vivo*. *Neuroreport* (1994) 5: 2298-2300
- (113) Bredt DS and Synder SH. Nitric oxide, a novel neuronal messenger. *Neuron* (1992) 8: 3-11
- (114) Afanasiev I, Ferger B and Kuschinsky K. The associative type of sensitization to d-amphetamine is expressed as an NO-dependent dramatic increase in extracellular dopamine in the nucleus accumbens. *Naunyn-Schmiedeberg's Arch. Pharmacol.* (2000) 362: 232-237
- (115) Ohno M, Aria I and Watanabe S. N-Methyl-D-aspartate stimulates dopamine release through nitric oxide formation in the nucleus accumbens of rats. *Brain Res.* (1995) 699: 332-335
- (116) Martin JL and Itzhak Y. 7-Nitroindazole blocks nicotine-induced conditioned place preference but not LiCl-induced conditioned place aversion. *Neuroreport.* (2000) 11: 947-9
- (117) Itzhak Y and Martin JL. Blockade of alcohol-induced locomotor sensitization and conditioned place preference in DBA mice by 7-nitroindazole. *Brain Res.* (2000) 858: 402-7
- (118) Atcheson R, Rowbotham DJ and Lambert DG. Fentanyl inhibits the release of [<sup>3</sup>H]noradrenaline from SH-SY5Y human neuroblastoma cells. *Br. J. Anaesth.* (1994) 72: 98-103
- (119) Brazell MP, Mitchell SN and Gray JA. Effect of acute administration of nicotine on *in vivo* release of noradrenaline in the hippocampus of freely moving rats; a dose response and the antagonists study. *Neuropharmacology* (1991) 30: 823-833
- (120) Maldoado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. *Neurosci. Biobehav. Rev.* (1997) 21: 91-104
- (121) Milne B, Cervencko FW, Jhamandas K, Loomis C and Sutak M. Analgesia and tolerance to intrathecal morphine and norepinephrine infusion via implanted mini-osmotic pumps in the rat. *Pain* (1985) 22: 165-172
- (122) Solomon RE and Gebhart GF. Intrathecal morphine and clonidine: antinociceptive tolerance and cross-tolerance and effects on blood pressure. *J. Pharmacol. Exp. Ther.* (1988) 245: 444-454
- (123) Paalzow G. Development of tolerance to analgesic effects of clonidine in rats cross-tolerant to morphine. *Naunyn-Schmiedeberg's* (1978) 304: 1-4
- (124) Kosten TA. Clonidine attenuates conditioned aversion produced by naloxene-precipitated opiate withdrawal. *Eur. J. Pharmacol.* (1994) 254: 59-63
- (125) Gold MS, Redmond DE and Kelger HD. Clonidine blocks acute opiate-withdrawal symptoms. *Lancet* (1987) 16: 599-602
- (126) Dwoskin LP, Neal BS and Sparber SB. Yohimbine exacerbates and clonidine attenuates acute morphine



- withdrawal in rats. *Eur. J. Pharmacol.* (1983) 90: 269-273
- (127) Iglesias V, Alguacil LF, Alamo C and Cuenca E. Effects of yohimbine on morphine analgesia and physical dependence in the rat. *Eur. J. Pharmacol.* (1992) 211: 35-38
- (128) Hughes CE, Habash T, Dykstra LA and Picker MJ. Discriminative-stimulus effects of morphine in combination with alfa-and beta-noradrenergic agonists and antagonists in rats. *Pharmacol. Biochem. Behav.* (1996) 53: 979-986
- (129) Schulteis G, Stinus L, Risbrough VB and Koob GF. Clonidine blocks acquisition but not expression of conditioned opiate withdrawal in rats. *Neuropsychopharmacology* (1998) 19: 406-416
- (130) Hoffman DC. The use of place conditioning in studying the neuropharmacology of drug reinforcement. *Brain Res. Bull.* (1989) 23: 373-387
- (131) Drouin C, Darracq L, Trovero F, Blanc G, Glowinski J and Cotecchi Tassin JP. Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. *J. Neurosci.* (2002) 22: 2873-2884
- (132) Zarrindast MR, Bahreini T and Adl M. Effect of imipramine on the expression and acquisition of morphine-induced conditioned place preference in mice. *Pharmacol. Biochem. Behav.* (2000) 73: 941- 949
- (133) Sahraei H, Ghazzaghi H, Zarrindast MR, Ghoshoonia H, Sepehri H, Haeri-Rohani A. The role of alpha-adrenoceptor mechanism(s) in morphine-induced conditioned place preference in female mice. *Pharmacol. Biochem. Behav.* (2004) 78: 135-141
- (134) Bozarth MA and Wise RA. Electolytic microinfusion transducer system: an alternative method of intracranial drug application. *J. Neurosci. Methods* (1980) 2: 273-275
- (135) Hand TH, Stinus L and Le Moal M. Differential mechanisms in the acquisition and expression of heroine-induced place preference. *Psychopharmacology* (1989) 98: 61-67
- (136) Nader K and Van der Kooy D. Clonidine antagonizes the aversive effects of opiate withdrawal and the rewarding effects of morphine only in opiate withdrawn rats. *Behav. Neurosci.* (1996) 110: 389- 400
- (137) Susset JG, Tessier CD, Winceze J, Bansal S, Malhorta C and Schwacha MG. Effect of yohimbine hydrochloride on erectile impotence: a double blind study. *J. Urol.* (1989) 141: 1360 - 1363
- (138) Rufollo Jr RR. a2-Adrenoceptor agonists and antagonists. *Neurotransmissions* (1990) 4: 1-5

---

This article is available online at <http://www.ijpr-online.com>